Modifier vs. Gene-Specific: What Sets OCU400 Apart in the Gene Therapy Landscape? | OCUGEN

OCU400: A Revolutionary Gene Therapy for Retinitis Pigmentosa Discover how OCU400, a novel modifier gene therapy, stands out as a groundbreaking treatment for inherited retinal diseases like retinitis pigmentosa. Unlike traditional gene augmentation, editing, or replacement therapies, OCU400 uses the NR2E3 master gene regulator to create a healthy environment for photoreceptors, addressing multiple genetic mutations. Dive into the details of its unique gene-agnostic approach, the ongoing phase three limelight trial, and its potential to treat 98-99% of genetic mutations related to retinitis pigmentosa, offering hope for those facing potential blindness. 00:00 Introduction to OCU400 Gene Therapy 00:18 Current Landscape of Retinitis Pigmentosa Treatments 00:53 The Role of NR2E3 in Gene Regulation 01:24 How OCU400 Works 02:05 Clinical Trials and Future Prospects 02:51 Conclusion and Summary